Charles River Laboratories International (NYSE:CRL) EVP Sells 981 Shares of Company Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 981 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $308.44, for a total transaction of $302,579.64. Following the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,482,671.08. This represents a 16.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

NYSE:CRL traded down $4.75 during midday trading on Wednesday, hitting $300.21. 1,242,167 shares of the stock were exchanged, compared to its average volume of 1,048,482. The company has a market capitalization of $14.33 billion, a price-to-earnings ratio of -61.90, a P/E/G ratio of 2.86 and a beta of 1.40. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. Charles River Laboratories International, Inc. has a one year low of $146.20 and a one year high of $333.30. The business has a 50-day moving average price of $281.78 and a two-hundred day moving average price of $221.18.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. During the same period last year, the firm earned $3.12 EPS. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 11.36 EPS for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

Institutional investors have recently bought and sold shares of the stock. Handelsbanken Fonder AB boosted its holdings in shares of Charles River Laboratories International by 36.9% in the second quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company’s stock worth $4,378,000 after buying an additional 5,200 shares during the period. Avidity Partners Management LP acquired a new stake in shares of Charles River Laboratories International during the first quarter valued at approximately $1,670,000. Quantitative Investment Management LLC acquired a new stake in shares of Charles River Laboratories International during the second quarter valued at approximately $1,360,000. Maverick Capital Ltd. purchased a new stake in shares of Charles River Laboratories International in the 1st quarter valued at approximately $1,411,000. Finally, Madison Asset Management LLC acquired a new position in Charles River Laboratories International in the 2nd quarter worth approximately $3,805,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International News Roundup

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analysts raised earnings forecasts. Zacks Research increased its FY2026 EPS estimate to $11.17 from $11.15, FY2027 to $12.54 from $12.49, and FY2028 to $13.92 from $13.82. It also made modest upward revisions to several quarterly estimates and maintained a “Strong-Buy” rating. Zacks Research earnings forecast
• Positive Sentiment: UBS upgraded CRL to Strong Buy, providing additional institutional support after the company’s substantial 12-month advance. UBS upgrade
• Positive Sentiment: Operational momentum remains a key bullish theme. Recent coverage points to improving Research Models and Services trends, expanding AI-enabled testing, healthy cash flow, and the ability to fund share buybacks and investment. Charles River rally analysis
• Positive Sentiment: Charles River and Autolomous launched Apollo Orchestrate, a digital laboratory-execution solution integrated within Charles River’s Apollo platform. The initiative could strengthen the company’s technology offering and improve laboratory efficiency. Apollo Orchestrate launch
• Neutral Sentiment: A Zacks comparison examines whether CRL or Progyny offers the more attractive value opportunity. The article may influence valuation-focused investors, but the headline does not disclose a definitive preference. PGNY versus CRL value analysis
• Negative Sentiment: Valuation and recent gains may be limiting near-term upside. With CRL near its 12-month high after a powerful rally, investors may be taking profits while awaiting further earnings confirmation. The company’s latest reported revenue declined 2.7% year over year, adding a reason for caution despite earnings beating estimates.

Wall Street Analyst Weigh In

CRL has been the topic of several research reports. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a research report on Monday, August 10th. Argus set a $330.00 price objective on shares of Charles River Laboratories International in a research report on Thursday, September 17th. Jefferies Financial Group lifted their price objective on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a research note on Monday, September 28th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Finally, Mizuho increased their target price on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the company a “neutral” rating in a research note on Friday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $300.11.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.